🔴 ANI Pharmaceuticals is trading 5.59% down today after reduced Cortrophin Gel revenue guidance

ANI Pharmaceuticals is trading 5.59% down at $78.02 after investors focused on reduced Cortrophin Gel revenue guidance.

• Q2 revenue reached $266 million, and adjusted EPS was $2.21, exceeding estimates.
• Cortrophin Gel guidance fell to $520–$540 million from $540–$575 million, while companywide guidance was reaffirmed.
• The move appears company-specific; no volume data was provided.